General Information of the Drug (ID: M6APDG03061)
Name
BLU-554
Synonyms
MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide
    Click to Show/Hide
Status
Phase 1
Structure
Formula
C24H24Cl2N4O4
InChI
1S/C24H24Cl2N4O4/c1-4-20(31)28-16-7-8-34-12-17(16)30-24-27-11-14-9-13(5-6-15(14)29-24)21-22(25)18(32-2)10-19(33-3)23(21)26/h4-6,9-11,16-17H,1,7-8,12H2,2-3H3,(H,28,31)(H,27,29,30)/t16-,17+/m0/s1
InChIKey
MGZKYOAQVGSSGC-DLBZAZTESA-N
PubChem CID
91885617
TTD Drug ID
D0XZ1D
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Fibroblast growth factor receptor 4 (FGFR4)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
Response Summary Fibroblast growth factor receptor 4 (FGFR4) is a therapeutic target for BLU-554. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BLU-554 through regulating the expression of Fibroblast growth factor receptor 4 (FGFR4). [1], [2]
References
Ref 1 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022 May 13;13(1):2672. doi: 10.1038/s41467-022-30217-7.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)